CVRdatabase
Menu

Acesion Pharma ApS

Private limited companyCVR 34083738FrederiksbergActive

Acesion Pharma ApS is a private limited company, based in Frederiksberg, active in research and experimental development on natural sciences and engineering, founded in 2011. The company made a loss in both 2024 and 2025, most recently DKK 59.6m. With 16 employees, the company is about 3 times larger than the industry median. Equity grew to DKK 276.1m in 2025.

Follow
PDF reportCompare

Key figures · financial year 2025

Net profit−DKK 59.6m−38.5% vs. 2024
EquityDKK 276.1m+208% vs. 2024
Employees16latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • The loss grew: from DKK 43m to DKK 59.6m (2024 → 2025).
  • Equity rose 208% (2024 → 2025), to DKK 276.1m.

Employees

  • 2 more employees than a year earlier: 16 (08/2026) against 14 (08/2025).

Management and owners, last 24 months

  • New owners registered: Novo Holdings A/S (22/12/2025), Canaan XII L.P. (22/12/2025) and Alpha Wave Ventures II, LP (22/12/2025) (+5).
  • No longer registered as owner: FC Inbio Holdings Limited (20/08/2025), Novo Holdings A/S (19/08/2025) and Canaan XII L.P. (19/08/2025) (+5).

Registrations, last 24 months

  • 22/12/2025: Share capital changed from 171,165,948 DKK to 189,063,037 DKK
  • 20/08/2025: Share capital changed from 115,238,238 DKK to 171,165,948 DKK
  • 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 100m−DKK 50mDKK 0DKK 50mDKK 100mDKK 150mDKK 200mDKK 250mDKK 300m202020212022202320242025
EquityNet profit
Financial figures for Acesion Pharma ApS
202020212022202320242025Change
Revenue00not statednot statednot statednot stated–
Operating profit (EBIT)−36,311−37,897−56,635−53,020−57,245−71,308−24.6%
Profit before tax−36,928−33,053−60,165−55,824−55,934−70,972−26.9%
Net profit−31,428−25,157−46,780−42,849−43,033−59,597−38.5%
Total assets64,53333,95453,191165,939116,146287,308+147.4%
Equity−20,04810,34422,983130,79989,642276,067+208%
Liabilities84,58123,61130,20835,14026,50411,241−57.6%
Cash and cash equivalents54,79324,22139,026149,104100,153199,971+99.7%
Average number of employees807711––

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 60m−DKK 50m−DKK 40m−DKK 30m−DKK 20m−DKK 10mDKK 0202020212022202320242025
Net profitMedian, the industry (431 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Loss for 6 years in a row

    Net result has been negative in 2020–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for Acesion Pharma ApS
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202501/07/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202425/06/2025The companyPDFXBRL
202301/01/2023 – 31/12/202306/06/2024The companyPDFXBRL
202201/01/2022 – 31/12/202213/06/2023The companyPDFXBRL
202101/01/2021 – 31/12/202107/07/2022The companyPDFXBRL
202001/01/2020 – 31/12/202014/06/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
024681012141609/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/2608/26
Employees

Position in the industry

431 companies in the database

Comparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.

EquityDKK 276.1mNo. 15 of 431
Better than 97% of the companies in the industry
Number of employees16No. 106 of 431
Better than 76% of the companies in the industry

Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.

DKK 100kDKK 2.5mDKK 63.4mDKK 1.6bnDKK 13.7bn
Distribution of gross profit for 250 companies in the industry (latest financial year, logarithmic scale).

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with fewer than 20 employees69,967 companies in the comparisonnot stated
No. 772of 69,964
Better than 99%
Same industry and fewer than 20 employees329 companies in the comparisonnot stated
No. 1of 329
Better than 100%
Companies that are between 5 and 14 years old33,688 companies in the comparisonnot stated
No. 316of 33,687
Better than 99%
All companies of type ApS66,508 companies in the comparisonnot stated
No. 423of 66,505
Better than 99%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Research and experimental development on natural sciences and engineering
Gross profit
  1. Acesion Pharma ApS–
  2. Carlsberg A/SDKK 40.2bn
  3. Zealand Pharma A/SDKK 9.2bn
Net profit
  1. Acesion Pharma ApS−DKK 59.6m
  2. Carlsberg A/SDKK 7bn
  3. Zealand Pharma A/SDKK 6.5bn
Equity
  1. Acesion Pharma ApSDKK 276.1m
  2. Carlsberg A/SDKK 30.7bn
  3. Zealand Pharma A/SDKK 14.8bn
Employees
  1. Acesion Pharma ApS16
  2. Carlsberg A/S107
  3. Zealand Pharma A/S569

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
Acesion Pharma ApS

Management

5 active registrations

Executive management

Executive management at Acesion Pharma ApS
NameRoleAppointed
Anders Gaarsdal HolstCEO01/06/2022

Board of directors

Board of directors at Acesion Pharma ApS
NameRoleAppointed
Jørgen Søberg PetersenChair of the board28/05/2020
Timothy Michael ShannonBoard member15/09/2023
Nik EconomopoulosBoard member15/09/2023
Benjamin Bruno ThornerBoard member28/02/2024
Founders
Ulrik Svane Sørensen, Morten Grunnet, PreSeed Ventures A/S, Novo Holdings A/S, Seed Capital Denmark Ii K/S
Former management (18)
Former management at Acesion Pharma ApS
NameRoleAppointedResigned
Frank KnudsenBoard member15/12/201101/08/2014
Ulrik Svane SørensenCEO15/12/201101/04/2016
Morten GrunnetBoard member15/12/201115/09/2023
Morten GrunnetDirector15/12/201102/05/2016
Bobby G SoniBoard member01/08/201415/08/2015
Ingelise SaundersChair of the board01/08/201428/05/2020
Carsten SchouBoard member01/08/201401/02/2016
Stephan ChristgauBoard member15/08/201509/09/2019
Paul David GoldenheimBoard member01/02/201628/05/2020
Frans Gustaf WuiteCEO01/04/201630/06/2020
Lars GredstedBoard member13/01/201725/10/2017
Jakob Dynnes HansenDirector17/03/201701/12/2018
Georgios TrichasBoard member25/10/201731/08/2018
Ann Mills-DugganBoard member22/10/201806/01/2022
Torgeir VaageDirector01/12/201801/06/2022
Duan XiangBoard member23/01/201909/09/2019
Morten DøssingBoard member09/09/201915/09/2023
Karen Juo-Lai ChuBoard member09/09/201915/09/2023

Signing rule: Selskabet tegnes af tre bestyrelsesmedlemmer eller af en direktør og bestyrelsesformanden i forening.

Address and production units

1 active production units

Nordre Fasanvej 215
2000 Frederiksberg

Frederiksberg Municipality · Postcode 2000

Other companies at the address (8)

  • Sparrow Quantum ApSManufacture of computers and peripheral equipment
  • Adcendo ApSResearch and experimental development on natural sciences and engineering
  • Hemab ApSManufacture of pharmaceutical preparations
  • Orbis Medicines ApSResearch and experimental development on natural sciences and engineering
  • Minervax ApSResearch and experimental development on natural sciences and engineering
Production units
Production unitAddressEmployeesP number
ACESION PHARMA ApSNordre Fasanvej 215, 2000 Frederiksberg161017343668

Purpose

Selskabets formål er at udvikle lægemidler til medicinsk behandling af atrieflimmer.

The purpose is quoted from the register in Danish.

Changes year by year

141 registered events
20261 changeaccounts 1
  • Annual report for 2025 published
202520 changescapital 2 · ownership 16 · accounts 1 · industry 1
  • Share capital changed from 171,165,948 DKK to 189,063,037 DKK
  • Novo Holdings A/S registered as owner (33.33%)
  • RMG-KB BioAccess Fund, L.P. registered as owner (5%)
  • Alpha Wave Ventures II, LP registered as owner (15%)
  • Canaan XII L.P. registered as owner (20%)
  • Canaan XII L.P. is no longer registered as owner
  • RMG-KB BioAccess Fund, L.P. is no longer registered as owner
  • Alpha Wave Ventures II, LP is no longer registered as owner
  • Novo Holdings A/S is no longer registered as owner
  • Share capital changed from 115,238,238 DKK to 171,165,948 DKK
  • Canaan XII L.P. registered as owner (20%)
  • RMG-KB BioAccess Fund, L.P. registered as owner (5%)
  • Alpha Wave Ventures II, LP registered as owner (15%)
  • Novo Holdings A/S registered as owner (33.33%)
  • FC Inbio Holdings Limited is no longer registered as owner
  • Canaan XII L.P. is no longer registered as owner
  • Alpha Wave Ventures II, LP is no longer registered as owner
  • Novo Holdings A/S is no longer registered as owner
  • Annual report for 2024 published
  • Industry changed to Research and experimental development on natural sciences and engineering (721000)
20243 changesaccounts 1 · address 1 · management 1
  • Annual report for 2023 published
  • Moved to Nordre Fasanvej 215, 2000 Frederiksberg
  • Benjamin Bruno Thorner appointed board member
202318 changesownership 11 · capital 1 · management 5 · accounts 1
  • Canaan XII L.P. registered as owner (15%)
  • Alpha Wave Ventures II, LP registered as owner (10%)
  • Novo Holdings A/S registered as owner (50%)
  • Novo Holdings A/S is no longer registered as owner
  • Alpha Wave Ventures II, LP is no longer registered as owner
  • Canaan XII L.P. is no longer registered as owner
  • Share capital changed from 70,496,070 DKK to 115,238,238 DKK
  • Nik Economopoulos appointed board member
  • Timothy Michael Shannon appointed board member
  • Morten Døssing stepped down as board member
  • Karen Juo-Lai Chu stepped down as board member
  • Morten Grunnet stepped down as board member
  • Novo Holdings A/S registered as owner (50%)
  • Alpha Wave Ventures II, LP registered as owner (10%)
  • Canaan XII L.P. registered as owner (15%)
  • The Wellcome Trust Limited as trustee of the Wellcome Trust is no longer registered as owner
  • Novo Holdings A/S is no longer registered as owner
  • Annual report for 2022 published
202212 changesownership 7 · accounts 1 · management 3 · capital 1
  • FC Inbio Holdings Limited registered as owner (5%)
  • Annual report for 2021 published
  • Anders Gaarsdal Holst appointed ceo
  • Torgeir Vaage stepped down as director
  • Share capital changed from 13,246,070 DKK to 70,496,070 DKK
  • The Wellcome Trust Limited as trustee of the Wellcome Trust registered as owner (5%)
  • Novo Holdings A/S registered as owner (66.67%)
  • FC Danishbio Holdings Limited is no longer registered as owner
  • Broadview Ventures I LLC is no longer registered as owner
  • Novo Holdings A/S is no longer registered as owner
  • The Wellcome Trust Limited as trustee of the Wellcome Trust is no longer registered as owner
  • Ann Mills-Duggan stepped down as board member
20216 changesaccounts 1 · capital 1 · ownership 4
  • Annual report for 2020 published
  • Share capital changed from 8,225,977 DKK to 13,246,070 DKK
  • Novo Holdings A/S registered as owner (50%)
  • FC Danishbio Holdings Limited registered as owner (5%)
  • Novo Holdings A/S is no longer registered as owner
  • FC Danishbio Holdings Limited is no longer registered as owner
20206 changescapital 1 · ownership 1 · management 4
  • Share capital changed from 7,548,114 DKK to 8,225,977 DKK
  • Uddannelses- og Forskningsstyrelsen is no longer registered as owner
  • Frans Gustaf Wuite stepped down as ceo
  • Jørgen Søberg Petersen appointed chair of the board
  • Paul David Goldenheim stepped down as board member
  • Ingelise Saunders stepped down as chair of the board
201916 changesmanagement 5 · capital 2 · ownership 9
  • Morten Døssing appointed board member
  • Karen Juo-Lai Chu appointed board member
  • Duan Xiang stepped down as board member
  • Stephan Christgau stepped down as board member
  • Share capital changed from 6,852,518 DKK to 7,548,114 DKK
  • The Wellcome Trust Limited as trustee of the Wellcome Trust registered as owner (25%)
  • The Wellcome Trust Limited as trustee of the Wellcome Trust is no longer registered as owner
  • Share capital changed from 5,155,497 DKK to 6,852,518 DKK
  • Duan Xiang appointed board member
  • Novo Holdings A/S registered as owner (33.33%)
  • FC Danishbio Holdings Limited registered as owner (10%)
  • The Wellcome Trust Limited as trustee of the Wellcome Trust registered as owner (20%)
  • Broadview Ventures I LLC registered as owner (5%)
  • Novo Holdings A/S is no longer registered as owner
  • The Wellcome Trust Limited as trustee of the Wellcome Trust is no longer registered as owner
  • Broadview Ventures I LLC is no longer registered as owner
201810 changesmanagement 4 · capital 2 · ownership 4
  • Torgeir Vaage appointed director
  • Jakob Dynnes Hansen stepped down as director
  • Share capital changed from 4,018,797 DKK to 5,155,497 DKK
  • Ann Mills-Duggan appointed board member
  • Novo Holdings A/S registered as owner (50%)
  • The Wellcome Trust Limited as trustee of the Wellcome Trust registered as owner (25%)
  • The Wellcome Trust Limited as trustee of the Wellcome Trust is no longer registered as owner
  • Novo Holdings A/S is no longer registered as owner
  • Georgios Trichas stepped down as board member
  • Share capital changed from 3,594,496 DKK to 4,018,797 DKK
20174 changesmanagement 4
  • Georgios Trichas appointed board member
  • Lars Gredsted stepped down as board member
  • Jakob Dynnes Hansen appointed director
  • Lars Gredsted appointed board member
201620 changescapital 3 · ownership 12 · management 5
  • Share capital changed from 3,088,397 DKK to 3,594,496 DKK
  • The Wellcome Trust Limited as trustee of the Wellcome Trust registered as owner (25%)
  • The Wellcome Trust Limited as trustee of the Wellcome Trust is no longer registered as owner
  • Share capital changed from 2,283,607 DKK to 3,088,397 DKK
  • Novo Holdings A/S registered as owner (33.33%)
  • Novo Holdings A/S is no longer registered as owner
  • Share capital changed from 1,849,327 DKK to 2,283,607 DKK
  • Uddannelses- og Forskningsstyrelsen registered as owner (5%)
  • The Wellcome Trust Limited as trustee of the Wellcome Trust registered as owner (20%)
  • Broadview Ventures I LLC registered as owner (5%)
  • PreSeed Ventures A/S registered as owner (10%)
  • PreSeed Ventures A/S is no longer registered as owner
  • Broadview Ventures I LLC is no longer registered as owner
  • The Wellcome Trust Limited as trustee of the Wellcome Trust is no longer registered as owner
  • PreSeed Ventures A/S is no longer registered as owner
  • Morten Grunnet stepped down as director
  • Frans Gustaf Wuite appointed ceo
  • Ulrik Svane Sørensen stepped down as ceo
  • Paul David Goldenheim appointed board member
  • Carsten Schou stepped down as board member
20158 changesmanagement 2 · ownership 5 · capital 1
  • Stephan Christgau appointed board member
  • Bobby G Soni stepped down as board member
  • Broadview Ventures I LLC registered as owner (10%)
  • The Wellcome Trust Limited as trustee of the Wellcome Trust registered as owner (25%)
  • PreSeed Ventures A/S registered as owner (20%)
  • Share capital changed from 1,313,022 DKK to 1,849,327 DKK
  • PreSeed Ventures A/S is no longer registered as owner
  • Broadview Ventures I LLC is no longer registered as owner
20149 changescapital 2 · ownership 3 · management 4
  • Share capital changed from 878,742 DKK to 1,313,022 DKK
  • PreSeed Ventures A/S registered as owner (25%)
  • Broadview Ventures I LLC registered as owner (20%)
  • Novo Holdings A/S registered as owner (33.33%)
  • Bobby G Soni appointed board member
  • Carsten Schou appointed board member
  • Ingelise Saunders appointed chair of the board
  • Frank Knudsen stepped down as board member
  • Share capital changed from 647,142 DKK to 878,742 DKK
20131 changecapital 1
  • Share capital changed from 361,428 DKK to 647,142 DKK
20122 changesaddress 1 · industry 1
  • Moved to Ole Maaløes Vej 3, 2200 København N
  • Industry changed to Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721900)
20115 changesfounded 1 · management 4
  • Registered as ACESION PHARMA ApS
  • Ulrik Svane Sørensen appointed ceo
  • Morten Grunnet appointed director
  • Morten Grunnet appointed board member
  • Frank Knudsen appointed board member

Related companies

Same industry in Frederiksberg

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.

View in CVRReport a correction